NCT05129319 is a EARLY_PHASE1 clinical trial of prabotulinumtoxinA in Glabellar Frown Lines, sponsored by Clinical Testing of Beverly Hills.

Who is sponsoring NCT05129319?

NCT05129319 is sponsored by Clinical Testing of Beverly Hills.

What drugs are being tested in NCT05129319?

Interventions in NCT05129319: prabotulinumtoxinA.

What condition does NCT05129319 study?

NCT05129319 studies Glabellar Frown Lines.

Is NCT05129319 still recruiting?

NCT05129319 is currently completed. Last updated 6 February 2024.

Last reviewed 2024-02-06 · How we verify

NCT05129319

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Completed EARLY_PHASE1 Last updated 6 February 2024

What this trial tests

EARLY_PHASE1 trial testing prabotulinumtoxinA in Glabellar Frown Lines in 30 participants. Completed in 15 June 2023.

Timeline

16 December 2021

Primary endpoint
15 June 2023

15 June 2023

Quick facts

Lead sponsor	Clinical Testing of Beverly Hills
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	16 December 2021
Primary completion	15 June 2023
Estimated completion	15 June 2023
Sites	1 location across United States

Drugs / interventions tested

prabotulinumtoxinA — full drug profile →

Conditions studied

Glabellar Frown Lines — all drugs for Glabellar Frown Lines →

Sponsor

Clinical Testing of Beverly Hills

Who can join

18 and older, female only, with Glabellar Frown Lines. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Clinical Testing of Beverly Hills trials

Trials by the same sponsor.

NCT06429033 — Purified Exosome Product (PEP) Injected Into the Hypodermis · Phase 1 · completed
NCT05083286 — Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines · EARLY_PHASE1 · unknown
NCT04886167 — Dysport Dose-Ranging Treatment of Platysmal Bands · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05129319 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinical Testing of Beverly Hills
Last refreshed: 6 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05129319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing